Effective price per mg uses an active dated override first, then the row-level historical discount, then the vendor default from the same Git revision. Aggregate chart points include exact-comparability offers only. Missing observations remain gaps; the series does not interpolate across unavailable offers or absent snapshots.

Price watch · beta

Let the market come to you.

Watch the best market price or one vendor. Get one email when TB-500 crosses your target, drops, or sets a new tracked low—without daily noise.

Price scopeAlert meTarget per mg

$/mg

Confirmed Weekly Peptide Intel email

Requires a confirmed Weekly Peptide Intel address, then a separate alert confirmation. Already watching? Manage price alerts. Public prices can change; confirm the final cart total.

Public product evidence832 certificate records mentioning this compound or product name454 provider-linked · 696 exact product matches

Status

Research Market

This name primarily lives in the research market and should not be read like an approved pharmaceutical product.

Research area

Tissue-repair research

Primary research area: Tissue repair. Also surfaces under Performance for browsing and discovery.

Aliases

Thymosin Beta-4 Fragment

Signal depth

Medium

No FDA label signal · 19 trials · 749 PubMed results

Promising

Research evidence

TB-500 has name-matched human trials with published or reported controlled evidence, but is not FDA-approved. The research is real and ongoing — treat findings as developing rather than settled.

TB-500 has 14 name-matched clinical trials (highest phase: Phase 2) and 749 PubMed-indexed publications and is not FDA-approved. 6 trials have posted results. Note: 4 retracted publications in the literature.

⚠ 4 retracted publications

Human data

Phase 2

Trial quality

Randomized

Outcomes

Clinical outcomes

Replication

Multiple trials

Literature

High-impact

PHASE2 · RandomizedRecombinant Human Thymosin Beta 4 for Injection(NL005) for Acute Myocardial Infarction PHASE2 · RandomizedEfficacy and Safety Study of Thymosin Beta 4 in Patients With Acute Myocardial Infarction PHASE1/PHASE2 · RandomizedTB-500 (Thymosin Beta 4 17-23 Fragment) for Cardiovascular Biomarkers in Stable ASCVD Molecular Biology of the Cell · 297 citationsThe control of actin nucleotide exchange by thymosin beta 4 and profilin. A potential regulatory mechanism for actin polymerization in cells.Proceedings of the National Academy of Sciences · 297 citationsComplete amino acid sequence of bovine thymosin beta 4: a thymic hormone that induces terminal deoxynucleotidyl transferase activity in thymocyte populations.Experimental Eye Research · 219 citationsThymosin Beta 4 Promotes Corneal Wound Healing and Decreases Inflammation in Vivo Following Alkali Injury

Evidence history

Re-checked nightly against the registries — tracked since 2026-07-09. No band changes yet.

Grades evidence strength, not efficacy or safety. Research-use context; not medical advice. Graded 2026-09-08 from PubMed, ClinicalTrials.gov, ISRCTN, openFDA, Health Canada, and OpenAlex — computed deterministically and refreshed nightly, with a retraction check. How we grade →

What TB-500 is

TB-500 is a synthetic peptide associated with the active region of thymosin beta-4. It appears frequently in injury-recovery discussions, especially around connective tissue, mobility, and return-to-training conversations.

Why it matters

Alongside BPC-157, TB-500 is one of the most recognizable names in the recovery bucket. Including it makes the recovery category feel much closer to what real users expect to see.

Regulatory context

TB-500 is not an FDA-approved recovery medicine in the United States. It is best understood as a research-market compound with strong community interest and much looser regulatory footing.

Practical reading note

This is another profile where popularity can outrun evidence quality quickly, so category clarity matters more than hype.